1. Identify the varying subtypes and prognostic features of CLL that impact treatment decisions.
2. Review literature on chemoimmunotherapy.
3. Understand the patient populations that are better served with targeted therapies.
12/08/2016 - 8:00am to 9:00am CST
Add to calendar:
- 1.00 AMA PRA Category 1 Credit™
- 1.00 Participation
Andrew Hantel, M.D.